Hongxia Lin - Concepedia

Author

Hongxia Lin

Rutgers, The State University of New Jersey

Also Known As

Glenn Forrester, Hong-Xia Lin, HongXia Lin, Hongxia Lin, Lin, Hongxia

Publications

714

Citations

H-Index

Concepts

All Affiliations

Rutgers, The State University of New Jersey Rutgers Cancer Institute Johnson University Duke Medical Center National Cancer Institute

About

Hongxia Lin is an author at Rutgers, The State University of New Jersey specializing in medicine, cancer research, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	83
2	Natural Sciences	1	1	10
3	Biochemistry	1	1	10
4	Cell Biology	1	1	10
5	Chemical Biology	1	1	10

Hongxia Lin

Publications

647

Citations

H-Index

Page 1

	Year	Citations
Targeting tumor metabolism with 2‐deoxyglucose in patients with castrate‐resistant prostate cancer and advanced malignancies Mark N. Stein, Hongxia Lin, Chandrika Jeyamohan, The Prostate	2010	288
A phase <scp>II</scp> trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (<scp>GRM</scp>1) signaling, in patients with advanced melanoma Janice M. Mehnert, Ann W. Silk, J. H. Lee, Pigment Cell & Melanoma Research	2018	51
Neutrophils Clear Bacteria Associated with Parasitic Nematodes Augmenting the Development of an Effective Th2-Type Response John Pesce, Zhugong Liu, Hossein A. Hamed, The Journal of Immunology	2008	46
Suppression of Cytosolic NADPH Pool by Thionicotinamide Increases Oxidative Stress and Synergizes with Chemotherapy Philip M. Tedeschi, Hongxia Lin, Murugesan Gounder, Molecular Pharmacology	2015	40
Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics Xin Yu, Samuel Kogan, Ying Chen, Clinical Cancer Research	2018	39
A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors Janice M. Mehnert, Amanda Kaveney, Jyoti Malhotra, Cancer Chemotherapy and Pharmacology GliomaMedicinePharmacologyPathologyAdvanced Solid Tumors	2019	30
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors Mark N. Stein, Susan Goodin, Murugeson Gounder, Investigational New Drugs OncologySolid TumorsMedicineAnti-cancer AgentCancer Treatment	2019	29
Quantification of folate metabolism using transient metabolic flux analysis Philip M. Tedeschi, Nadine Johnson-Farley, Hongxia Lin, Cancer & Metabolism	2015	23
Activated matriptase as a target to treat breast cancer with a drug conjugate Gulam M. Rather, Siang-Yo Lin, Hongxia Lin, Oncotarget	2018	16
BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study Quincy S. Chu, Natasha B. Leighl, Veerle Surmont, JTO Clinical and Research Reports	2022	16

Page 1